| Analysis | Samples | Factors | Units |
|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#45 - 5 | hours:0.17 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#10 - 5 | hours:0.17 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#45 - 5 | hours:0.17 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#46 - 6 | hours:0.17 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#11 - 6 | hours:0.17 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#46 - 6 | hours:0.17 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#50 - 10 | hours:0.17 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#15 - 10 | hours:0.17 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#50 - 10 | hours:0.17 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#49 - 9 | hours:0.17 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#14 - 9 | hours:0.17 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#49 - 9 | hours:0.17 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#44 - 4 | hours:0.17 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#9 - 4 | hours:0.17 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#44 - 4 | hours:0.17 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#43 - 3 | hours:0.17 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#8 - 3 | hours:0.17 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#43 - 3 | hours:0.17 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#47 - 7 | hours:0.17 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#12 - 7 | hours:0.17 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#47 - 7 | hours:0.17 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#48 - 8 | hours:0.17 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#13 - 8 | hours:0.17 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#48 - 8 | hours:0.17 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#42 - 2 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10m_1h_#52 - 12 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#17 - 12 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4und5_48h_10min_#7 - 2 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#42 - 2 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140311_AP6_10min_#52 - 12 | hours:0.17 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#10 - 5 | hours:1 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#45 - 5 | hours:1 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#45 - 5 | hours:1 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#11 - 6 | hours:1 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#46 - 6 | hours:1 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#46 - 6 | hours:1 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#15 - 10 | hours:1 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#50 - 10 | hours:1 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#50 - 10 | hours:1 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#14 - 9 | hours:1 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#49 - 9 | hours:1 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#49 - 9 | hours:1 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#9 - 4 | hours:1 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#44 - 4 | hours:1 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#44 - 4 | hours:1 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#8 - 3 | hours:1 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#43 - 3 | hours:1 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#43 - 3 | hours:1 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#12 - 7 | hours:1 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#47 - 7 | hours:1 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#47 - 7 | hours:1 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#13 - 8 | hours:1 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#48 - 8 | hours:1 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#48 - 8 | hours:1 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#17 - 12 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_10min_1h_#7 - 2 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#42 - 2 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#52 - 12 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#42 - 2 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140312_AP6_1h_#52 - 12 | hours:1 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#30 - 5 | hours:24 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#45 - 5 | hours:24 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#19 - 5 | hours:24 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#31 - 6 | hours:24 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#46 - 6 | hours:24 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#20 - 6 | hours:24 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#35 - 10 | hours:24 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#50 - 10 | hours:24 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#24 - 10 | hours:24 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#34 - 9 | hours:24 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#49 - 9 | hours:24 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#23 - 9 | hours:24 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#29 - 4 | hours:24 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#44 - 4 | hours:24 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#18 - 4 | hours:24 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#28 - 3 | hours:24 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#43 - 3 | hours:24 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#17 - 3 | hours:24 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#32 - 7 | hours:24 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#47 - 7 | hours:24 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#21 - 7 | hours:24 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#33 - 8 | hours:24 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#48 - 8 | hours:24 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#22 - 8 | hours:24 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#27 - 2 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140213_AP4_6h_24_restart_#37 - 12 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#42 - 2 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140227_AP5_24h_48h_#52 - 12 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#16 - 2 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140314_AP6_24h_#26 - 12 | hours:24 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#45 - 5 | hours:48 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#19 - 5 | hours:48 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#58 - 5 | hours:48 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#46 - 6 | hours:48 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#20 - 6 | hours:48 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#59 - 6 | hours:48 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#50 - 10 | hours:48 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#24 - 10 | hours:48 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#63 - 10 | hours:48 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#49 - 9 | hours:48 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#23 - 9 | hours:48 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#62 - 9 | hours:48 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#44 - 4 | hours:48 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#18 - 4 | hours:48 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#57 - 4 | hours:48 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#43 - 3 | hours:48 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#17 - 3 | hours:48 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#56 - 3 | hours:48 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#47 - 7 | hours:48 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#21 - 7 | hours:48 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#60 - 7 | hours:48 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#48 - 8 | hours:48 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#22 - 8 | hours:48 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#61 - 8 | hours:48 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#42 - 2 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140214_AP4and5_48h_10min_#52 - 12 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#16 - 2 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140228_AP5_24h_48h_#26 - 12 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#55 - 2 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140321_Betti_AP6_48h_#65 - 12 | hours:48 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#45 - 5 | hours:6 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#110 - 5 | hours:6 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#45 - 5 | hours:6 | treatment:CHX | concentration:20 µg/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#46 - 6 | hours:6 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#111 - 6 | hours:6 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#46 - 6 | hours:6 | treatment:ETO | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#50 - 10 | hours:6 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#115 - 10 | hours:6 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#50 - 10 | hours:6 | treatment:MC | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#49 - 9 | hours:6 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#114 - 9 | hours:6 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#49 - 9 | hours:6 | treatment:Serum | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#44 - 4 | hours:6 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#109 - 4 | hours:6 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#44 - 4 | hours:6 | treatment:STS | concentration:0.3 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#43 - 3 | hours:6 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#108 - 3 | hours:6 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#43 - 3 | hours:6 | treatment:TNFα | concentration:10 ng/ml | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#47 - 7 | hours:6 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#112 - 7 | hours:6 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#47 - 7 | hours:6 | treatment:TPG | concentration:2 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#48 - 8 | hours:6 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#113 - 8 | hours:6 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#48 - 8 | hours:6 | treatment:VAL | concentration:10 µM | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#42 - 2 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140211_AP4_6h_24h_#52 - 12 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#107 - 2 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140217_AP5_1h_6h_#117 - 12 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#42 - 2 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
| Reversed phase NEGATIVE ION MODE | HP_140313_AP6_6h_24h_#52 - 12 | hours:6 | treatment:vehicle (DMSO) | concentration:- | Relative intensity |
Return to study ST001740 main page
Download data matrix(Timecourse of NIH-3T3 cells treated with apoptotic inducers Reversed phase NEGATIVE ION MODE)
- Metabolomics Workbench
|